JPH0135666B2 - - Google Patents
Info
- Publication number
- JPH0135666B2 JPH0135666B2 JP56002392A JP239281A JPH0135666B2 JP H0135666 B2 JPH0135666 B2 JP H0135666B2 JP 56002392 A JP56002392 A JP 56002392A JP 239281 A JP239281 A JP 239281A JP H0135666 B2 JPH0135666 B2 JP H0135666B2
- Authority
- JP
- Japan
- Prior art keywords
- artificial
- tubular
- immobilized
- tubular body
- blood vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002473 artificial blood Substances 0.000 claims description 24
- 210000004204 blood vessel Anatomy 0.000 claims description 24
- 210000000056 organ Anatomy 0.000 claims description 24
- 210000003238 esophagus Anatomy 0.000 claims description 10
- 210000003437 trachea Anatomy 0.000 claims description 9
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 230000008520 organization Effects 0.000 description 10
- 208000031481 Pathologic Constriction Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000036262 stenosis Effects 0.000 description 7
- 208000037804 stenosis Diseases 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 239000004809 Teflon Substances 0.000 description 4
- 229920006362 Teflon® Polymers 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001732 thrombotic effect Effects 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920004934 Dacron® Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ICGQLNMKJVHCIR-UHFFFAOYSA-N 1,3,2-dioxazetidin-4-one Chemical group O=C1ONO1 ICGQLNMKJVHCIR-UHFFFAOYSA-N 0.000 description 1
- PUKLCKVOVCZYKF-UHFFFAOYSA-N 1-[2-(2,5-dioxopyrrol-1-yl)ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCN1C(=O)C=CC1=O PUKLCKVOVCZYKF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002085 Dialdehyde starch Polymers 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000005496 phosphonium group Chemical group 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium group Chemical group [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56002392A JPS57115250A (en) | 1981-01-09 | 1981-01-09 | Tubular artificial organ |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP56002392A JPS57115250A (en) | 1981-01-09 | 1981-01-09 | Tubular artificial organ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57115250A JPS57115250A (en) | 1982-07-17 |
JPH0135666B2 true JPH0135666B2 (enrdf_load_stackoverflow) | 1989-07-26 |
Family
ID=11527957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56002392A Granted JPS57115250A (en) | 1981-01-09 | 1981-01-09 | Tubular artificial organ |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57115250A (enrdf_load_stackoverflow) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2084057C (en) * | 1991-03-29 | 1999-12-07 | Yasuhiro Okuda | Composite artificial blood vessel |
TW510803B (en) * | 1996-11-20 | 2002-11-21 | Yasuhiko Shimizu | Man-made esophagus and its manufacturing method |
-
1981
- 1981-01-09 JP JP56002392A patent/JPS57115250A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS57115250A (en) | 1982-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920000459B1 (ko) | 다당류 유도체가 도포된 인공혈관과 그 제조방법 | |
EP0941740B1 (en) | Attachment of biomolecules to surfaces of medical devices | |
JP2815752B2 (ja) | 人工血管及びその製造方法 | |
US6303179B1 (en) | Method for attachment of biomolecules to surfaces through amine-functional groups | |
JP3784798B2 (ja) | ポリテトラフルオロエチレン製の埋め込み可能なチューブ状プロテーゼ | |
Jonas et al. | Biological sealants and knitted Dacron: porosity and histological comparisons of vascular graft materials with and without collagen and fibrin glue pretreatments | |
JPH0211258B2 (enrdf_load_stackoverflow) | ||
JPH0575429B2 (enrdf_load_stackoverflow) | ||
JP2008519626A (ja) | 治療用分子の徐放および遅延放出に用いる吸収特性が向上したシクロデキストリンを有する生体材料 | |
EP0212209B1 (en) | A production process of an antithrombogenic and antiadhesive material for medical use | |
US4695281A (en) | Medical material | |
KR20120087049A (ko) | 친수성기가 도입된 인공혈관 | |
JPH0135666B2 (enrdf_load_stackoverflow) | ||
Guidoin et al. | A compound arterial prosthesis: the importance of the sterilization procedure on the healing and stability of albuminated polyester grafts | |
CN114681685B (zh) | 杂化蛋白涂层的制备方法、杂化蛋白涂层材料及应用 | |
JPS61263448A (ja) | 血管補綴物 | |
JP2010508109A (ja) | 多孔質材製のベースエレメントから埋め込み型プロテーゼを製造する方法、それに関するプロテーゼ、および、その使用 | |
RU2135214C1 (ru) | Способ предымплантационной обработки текстильных изделий для сердечно- сосудистой хирургии | |
WO2018139665A1 (ja) | 血管内皮系細胞に特異的に結合するペプチドの使用、及びペプチド | |
EP0124659A1 (en) | Medical material | |
JPH0833661A (ja) | 人工血管及びその製造方法 | |
JPS63290573A (ja) | ヘパリン緩放出用医療装置 | |
JP3141653B2 (ja) | 人工血管 | |
Noishiki et al. | Polyepoxy compound fixation | |
JPS60220068A (ja) | 生体被覆膜 |